Transmedics Group Inc
NASDAQ:TMDX

Watchlist Manager
Transmedics Group Inc Logo
Transmedics Group Inc
NASDAQ:TMDX
Watchlist
Price: 62.87 USD -1.61%
Market Cap: 2.1B USD
Have any thoughts about
Transmedics Group Inc?
Write Note

Transmedics Group Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Transmedics Group Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Transmedics Group Inc
NASDAQ:TMDX
Total Equity
$209.9m
CAGR 3-Years
39%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Total Equity
$25.9B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
18%
Boston Scientific Corp
NYSE:BSX
Total Equity
$20.7B
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
12%
Stryker Corp
NYSE:SYK
Total Equity
$20.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Total Equity
$39.8B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Equity
$15.6B
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
18%
No Stocks Found

Transmedics Group Inc
Glance View

Market Cap
2.1B USD
Industry
Health Care

TransMedics Group Inc. emerged as a pioneering force within the medical technology sphere, aiming to revolutionize the organ transplant landscape. Founded with the bold vision of enhancing the viability of donor organs, TransMedics has developed the Organ Care System (OCS) — a portable, medical device designed to keep human organs alive and functioning outside of the body. The OCS effectively mimics the internal conditions of a human body, providing a nurturing environment that maintains organs in a near-living state. This innovation helps extend the time that organs can be viably transplanted, thereby increasing the success rates of transplants and offering a lifeline to individuals on long waiting lists. Monetizing this groundbreaking technology, TransMedics operates primarily through sales of its OCS products and related consumables, catering to well-established transplant centers worldwide. The company also taps into service agreements and training packages, ensuring that their clients can maximize the use and benefits of their products with the highest proficiency. In doing so, TransMedics not only empowers surgeons and hospitals to perform more successful transplants but also strengthens its position as a leading provider in a niche yet critical market. By addressing the challenges of organ preservation and transportation, TransMedics creates a compelling business model rooted in providing invaluable solutions for the healthcare industry and, ultimately, improving patient outcomes on a global scale.

TMDX Intrinsic Value
41 USD
Overvaluation 35%
Intrinsic Value
Price

See Also

What is Transmedics Group Inc's Total Equity?
Total Equity
209.9m USD

Based on the financial report for Sep 30, 2024, Transmedics Group Inc's Total Equity amounts to 209.9m USD.

What is Transmedics Group Inc's Total Equity growth rate?
Total Equity CAGR 5Y
27%

Over the last year, the Total Equity growth was 66%. The average annual Total Equity growth rates for Transmedics Group Inc have been 39% over the past three years , 27% over the past five years .

Back to Top